REDUCING BUDGET IMPACT TO MEXICAN PUBLIC HEALTH CARE SYSTEM WITH THE USAGE OF A NOVEL GLP-1 ANALOGUE FOR UNCONTROLLED T2DM PATIENTS ON BASAL INSULIN REGIMEN
Author(s)
Soria-Cedillo IF*1, Nevarez A2 1Sanofi, Mexico City, Mexico, 2Public Health Care System, Mexico City, Mexico
OBJECTIVES: To estimate annual savings in Mexican public health care system by the usage of lixisenatide for the treatment of uncontrolled type-2 diabetes mellitus patients on basal insulin. METHODS: Two different GLP-1 analogues (lixisenatide vs exenatide ) were evaluated from the perspective of public institution. A cost-minimization and budget impact analysis were conducted. Clinical efficacy was proved to be similar according to reported outcomes on a head-to-head clinical trial which included Mexican patients comparing the once-a-day administration of lixisenatide 20µg vs exenatide 10µg bid. Clinical response on 364 patients was evaluated; no statistical significance difference on reduction for fasting and postprandial glucose levels, as well as corporal weight loss, was reported; adverse events appeared to be less frequent on lixisenatide group than in exenatide group. Direct costs were considered on a decision tree with a temporary horizon of one year. No discount rate was included. Sensitivity analysis results on variables with highest degree of uncertainty were developed. Budget impact analysis was applied to different scenarios varying the estimated number of candidate patients to GLP-1 analogue treatment based on recent results reported on National Survey of Health and Nutrition 2012 (ENSANUT 2012). RESULTS: Estimated annual savings account for 279,000 USD. Budget impact reduction was established in 0.0008% for national public expenses in health and 0.0099% for therapeutic goods expenses in main public health institution in Mexico. Sensitivity analysis, showed robustness with base case. Market share scenarios, showed that increasing percentage of penetration (PP) of lixisenatide usage may result in lower impact to institutional budget (5.5 million USD for 0% PP to 5.2 million USD for 100% PP) CONCLUSIONS: Glycemic goal level in type-2 diabetes patients can be achieved with the synergy of insulin and lixisenatide with a corporal weight reduction and cost savings compared to exenatide usage.
Conference/Value in Health Info
2013-05, ISPOR 2013, New Orleans, LA, USA
Value in Health, Vol. 16, No. 3 (May 2013)
Code
PDB26
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Diabetes/Endocrine/Metabolic Disorders